In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.

by Antonio L Dans, Koon Teo, Peggy Gao, Jyh-Hong Chen, Kim Jae-Hyung, Khalid Yusoff, Suphachai Chaithiraphan, Jun Zhu, Liu Lisheng, Salim Yusuf, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial Investigators
Published 2010-12-01